Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31, 2009 must be consecutively screened and, if eligible, enrolled. Patients will be followed up at maximum until August 31, 2011. Switch to any other Anti vascUlar endothelial growth factor (anti VEGF) treatment will be documented and followed up. For each patient, demographics, medical history, administered treatments, results of ocular and visual assessments and other tests (where available) will be documented.
Study Type
OBSERVATIONAL
Enrollment
2,609
Patients with wet AMD treated with ranibizumab as prescribed by physician
Unnamed facility
Many Locations, Australia
Unnamed facility
Many Locations, Canada
Unnamed facility
Many Locations, France
Unnamed facility
Many Locations, Germany
Unnamed facility
Many Locations, Ireland
Unnamed facility
Many Locations, Italy
Unnamed facility
Many Locations, Japan
Unnamed facility
Many Locations, Netherlands
Unnamed facility
Many Locations, United Kingdom
Unnamed facility
Many Locations, Venezuela
Changes in visual acuity after start of Anti vascUlar endothelial growth factor (anti VEGF) therapy with ranibizumab, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or Snellen chard
Time frame: Baseline and 24 months
Demographic characteristics of patients included in the study (Age, Sex, Race)
Time frame: Baseline
Mean time from first clinical presentation to diagnosis
Time frame: Time from first clinical presentation to diagnosis: Up to 36 months
Mean time from diagnosis to treatment
Time frame: Time from diagnosis to treatment: Up to 24 months
Mean time from diagnosis to end of follow-up
Time frame: Time from diagnosis to end of follow-up: 48 months
Mean change of visual acuity, from diagnosis to end of follow-up, assessed by Early Treatment Diabetic Retinopathy (ETDRS) or SNELLEN
Time frame: Baseline and 24 months
Mean change of retinal thickness from diagnosis to end of follow-up, assessed by Optical Coherence Tomography (OCT)
Time frame: Baseline and 24 months
Mean change of lesion size from diagnosis to end of follow-up, assessed by Fluorescein Angiography (FA)
Time frame: Baseline and 24 months
Average number of treatments given from diagnosis to end of follow-up
Time frame: After 24 months
Vital Signs (blood pressure, heart rate, temperature) of patients included in the study
Time frame: Baseline
Medical and surgical history (diseases and surgeries) of patients included in the study
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.